SeaCrest Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

SeaCrest Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-400	Closed	-$7K	–	1392
2019 Q1	$7K	Sell	400 -1,000	-71%	-$14.9K	﹤0.01%	1632
2018 Q4	$19K	Sell	1,400 -200	-13%	-$3.72K	﹤0.01%	1256
2018 Q3	$46K	Buy	1,600 +210	+15%	+$6.11K	0.01%	1039
2018 Q2	$38K	Buy	1,390 +1,335	+2,427%	+$32.3K	0.01%	1090
2018 Q1	$1K	Buy	+55	New	+$1.35K	﹤0.01%	2111

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SeaCrest Wealth Management's NTLA Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Intellia Therapeutics (NTLA) in Q2 2019, closing a stake of 400 shares — an estimated $7K sold.

SeaCrest Wealth Management first reported a position in NTLA in Q1 2018 and held it in 5 quarters. The position peaked at $46K in Q3 2018. 144 funds tracked by Wall St. Rank hold NTLA as of Q2 2019.

SeaCrest Wealth Management reported no remaining Intellia Therapeutics position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 400 Intellia Therapeutics shares in Q2 2019, an estimated $7K.
SeaCrest Wealth Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 5 quarters.
SeaCrest Wealth Management's Intellia Therapeutics position peaked at $46K in Q3 2018.
144 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.